Mike Mattie

Corrigendum to ‘In Vitro and In Vivo Characterization of Axicabtagene Ciloleucel Identifies Features Associated with Treatment Resistance in Patients, Including a Dysfunctional CD8+ T Cell State Characterized By Overexpression of GATA3 Transcript’ Transplantation and Cellular Therapy Volume 31 (2025), Issue 2, Supplement, S57

Soumya Poddar, Gabriela Balderrama-Gutierrez, Chad Williams, Subing Cao et autres

Comparative pharmacokinetic derivations for axicabtagene ciloleucel and brexucabtagene autoleucel in the treatment of B cell malignancies

Shruti Sanjay Salunkhe, Jenny Nater, Colleen Schweitzer, Daqin Mao et autres

Axicabtagene ciloleucel (axi-cel) and brexucabtagene autoleucel (brexu-cel) are autologous anti-CD19 chimeric antigen receptor (CAR) T cell products originally approved in the pivotal ZUMA-1 and ZUMA-2 clinical studies for the treatment of relapsed/refractory (r/r) large B cell lymphoma (r/r LBCL) and r/r mantle …

au (code pays fourni par la source)

Supplementary Methods S1 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

Michael D. Jain, David B. Miklos, Caron A. Jacobson, John M. Timmerman et autres

SUPPLEMENTARY METHODS

Supplementary Figure S7 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

Michael D. Jain, David B. Miklos, Caron A. Jacobson, John M. Timmerman et autres

Serum IFNγ, IL-10, and IL-2 AUC0–28 (ng/mL)

Supplementary Table S2 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

Michael D. Jain, David B. Miklos, Caron A. Jacobson, John M. Timmerman et autres

Peak Concentration and AUC0–29 of Serum Utomilumab

Supplementary Figure S6 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

Michael D. Jain, David B. Miklos, Caron A. Jacobson, John M. Timmerman et autres

Correlation of Axi-cel CAR T-cell Peak With Utomilumab Dose and Peak Exposure

Supplementary Table S1 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

Michael D. Jain, David B. Miklos, Caron A. Jacobson, John M. Timmerman et autres

Representativeness of Study Participants

Supplementary Figure S1 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

Michael D. Jain, David B. Miklos, Caron A. Jacobson, John M. Timmerman et autres

ZUMA-11 Study Schema

Supplementary Figure S3 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

Michael D. Jain, David B. Miklos, Caron A. Jacobson, John M. Timmerman et autres

Patient Disposition

Supplementary Figure S2 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

Michael D. Jain, David B. Miklos, Caron A. Jacobson, John M. Timmerman et autres

CRS and NE Management Algorithms (1)

Supplementary Figure S8 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

Michael D. Jain, David B. Miklos, Caron A. Jacobson, John M. Timmerman et autres

CCR7 and CD45RA T-cell Phenotypes After Axi-cel and Utomilumab Infusions

Supplementary Figure S5 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

Michael D. Jain, David B. Miklos, Caron A. Jacobson, John M. Timmerman et autres

Ex vivo Axi-cel Proliferation After Stimulation With Utomilumab